INOVIO Reports Groundbreaking Results in COVID-19 Antibody Trial
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal antibodies (DMAbs) for COVID-19. Impressively, 100% of participants who reached …
INOVIO Reports Groundbreaking Results in COVID-19 Antibody Trial Read More